Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
BioCryst Pharmaceuticals (BCRX) has been drawing attention after a mixed run in its shares, with a one-month return of about a 12% decline and a three-month return of about a 6% decline. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $6.79, BioCryst Pharmaceuticals has experienced short term share price pressure, with a 30 day share price return of 11.82% and a year to date share price return of 9.47%. In contrast, the 1 year total shareholder return of 11.13% and 3 year total shareholder return of 35.82% indicate weaker longer term results. This suggests that recent upticks may reflect shifting views on its rare disease pipeline and risk profile rather than a sustained trend. If you are looking beyond a single biotech name, this could be a useful moment to scan other healthcare stocks that fit your own risk and return preferences. So with BioCryst trading at $6.79, annual revenue of about $599.8 million and a recent net loss of $8.8 million, is the
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema GlobeNewswire
- BioCryst: The $700 Million Pivot From Oral Convenience To Injectable [Seeking Alpha]Seeking Alpha
- Astria Stockholders Vote to Approve Acquisition by BioCryst [Yahoo! Finance]Yahoo! Finance
- BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 11/3/25 - Beat
BCRX
Sec Filings
- 1/27/26 - Form 4
- 1/27/26 - Form 3
- 1/23/26 - Form 8-K/A
- BCRX's page on the SEC website